Cellectis schedules Sept. 14 business update call
Rhea-AI Filing Summary
Cellectis S.A. (CLLS), a clinical-stage biotechnology company focused on gene-edited cell and gene therapies, announced it will host a conference call and webcast on September 14, 2026 to provide a business update. The company will hold an English-language call at 8:00 a.m. ET / 2:00 p.m. CET, followed by a French-language call at 9:00 a.m. ET / 3:00 p.m. CET. Both events will be accessible via webcast and telephone, with a replay available on the company’s website.
Cellectis develops allogeneic CAR T immunotherapies and other gene therapies using its in-house gene-editing and manufacturing platform, with headquarters in Paris and additional locations in New York and Raleigh, NC.
Positive
- None.
Negative
- None.
Key Figures
Business update date: September 14, 2026
English call time: 8:00 a.m. ET / 2:00 p.m. CET
French call time: 9:00 a.m. ET / 3:00 p.m. CET
+2 more
5 metrics
Business update date
September 14, 2026
Date of scheduled conference call and webcast
English call time
8:00 a.m. ET / 2:00 p.m. CET
Start time for English-language business update call
French call time
9:00 a.m. ET / 3:00 p.m. CET
Start time for French-language business update call
U.S. phone numbers
+1 (800) 717 1738; +1 (646) 307 1865
Dial-in options for both English and French calls
France toll-free number
+33 (800) 945 120
France toll-free dial-in for both calls
Key Terms
gene-editing platform, allogeneic, CAR T immunotherapies, off-the-shelf
4 terms
gene-editing platform technical
"a clinical-stage biotechnology company using its pioneering gene editing platform"
allogeneic medical
"The company utilizes an allogeneic approach for CAR T immunotherapies"
Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.
CAR T immunotherapies medical
"an allogeneic approach for CAR T immunotherapies in oncology"
off-the-shelf medical
"pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells"
Off-the-shelf describes products, software, medical devices, or solutions that are commercially available and ready to use without custom design or development. Investors care because off-the-shelf items typically cost less and reach the market faster than bespoke alternatives, reducing project risk and expense; like buying a ready-made appliance instead of commissioning a custom-built one, they offer predictable performance and clearer regulatory and cost forecasts.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Cellectis S.A. (CLLS) announce in this Form 6-K?
Cellectis announced it will host a conference call and webcast on September 14, 2026 to provide a business update, offering separate English- and French-language sessions accessible via webcast and phone, with a replay available on the company’s website.
When is Cellectis (CLLS) holding its English-language business update call?
The English-language business update call is scheduled for September 14, 2026 at 8:00 a.m. ET / 2:00 p.m. CET. It will be accessible via a webcast link and U.S. and France toll-free phone numbers provided in the announcement.
When is Cellectis (CLLS) holding its French-language business update call?
The French-language business update call is scheduled for September 14, 2026 at 9:00 a.m. ET / 3:00 p.m. CET. Investors can join through the specified webcast link or by using the listed U.S. and France toll-free phone numbers.
How can investors access the Cellectis (CLLS) September 14, 2026 webcasts?
Investors can access the webcasts via the two specific webcast links included for the English and French calls, or by dialing the listed phone numbers, including U.S. and France toll-free options. A replay will be available on Cellectis’ website following the event.
What does Cellectis (CLLS) do as a business?
Cellectis is a clinical-stage biotechnology company using a gene-editing platform to develop allogeneic CAR T immunotherapies in oncology and gene therapies in other indications. It has in-house manufacturing and locations in Paris, New York, and Raleigh, NC.
AI-generated analysis. How Rhea-AI works. Not financial advice.
